Literature DB >> 15660396

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.

Dimitri Lavillette1, Alexander W Tarr, Cécile Voisset, Peggy Donot, Birke Bartosch, Christine Bain, Arvind H Patel, Jean Dubuisson, Jonathan K Ball, François-Loïc Cosset.   

Abstract

Because of the lack of a robust cell culture system, relatively little is known about the molecular details of the cell entry mechanism for hepatitis C virus (HCV). Recently, we described infectious HCV pseudo-particles (HCVpp) that were generated by incorporating unmodified HCV E1E2 glycoproteins into the membrane of retroviral core particles. These initial studies, performed with E1E2 glycoproteins of genotype 1, noted that HCVpp closely mimic the cell entry and neutralization properties of parental HCV. Because sequence variations in E1 and E2 may account for differences in tropism, replication properties, neutralization, and response to treatment in patients infected with different genotypes, we investigated the functional properties of HCV envelope glycoproteins from different genotypes/subtypes. Our studies indicate that hepatocytes were preferential targets of infection in vitro, although HCV replication in extrahepatic sites has been reported in vivo. Receptor competition assays using antibodies against the CD81 ectodomain as well as ectopic expression of CD81 in CD81-deficient HepG2 cells indicated that CD81 is used by all the different genotypes/subtypes analyzed to enter the cells. However, by silencing RNA (siRNA) interference assays, our results show that the level of Scavenger Receptor Class-B Type-I (SR-BI) needed for efficient infection varies between genotypes and subtypes. Finally, sera from chronic HCV carriers were found to exhibit broadly reactive activities that inhibited HCVpp cell entry, but failed to neutralize all the different genotypes. In conclusion, we characterize common steps in the cell entry pathways of the major HCV genotypes that should provide clues for the development of cell entry inhibitors and vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660396     DOI: 10.1002/hep.20542

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  117 in total

1.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

2.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 3.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

Authors:  Thomas Pietschmann; Artur Kaul; George Koutsoudakis; Anna Shavinskaya; Stephanie Kallis; Eike Steinmann; Karim Abid; Francesco Negro; Marlene Dreux; Francois-Loic Cosset; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

6.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

8.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

9.  Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.

Authors:  Anne K Schwarz; Joe Grove; Ke Hu; Christopher J Mee; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

10.  Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.

Authors:  Baptiste Jammart; Maud Michelet; Eve-Isabelle Pécheur; Romain Parent; Birke Bartosch; Fabien Zoulim; David Durantel
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.